Dorzolamide
FDA Approved
Description
Dorzolamide is a carbonic anhydrase inhibitor used topically to reduce intraocular pressure. It is indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. In Harboyan syndrome, which presents with congenital hereditary endothelial dystrophy and progressive sensorineural deafness, dorzolamide may be used to manage corneal edema and associated elevated intraocular pressure.
Indications & Therapeutic Use
elevated intraocular pressure, open-angle glaucoma, ocular hypertension, corneal edema management
Linked Diseases:
Harboyan syndrome
C535473
Global Availability (7 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Dorzolamide
| Generic Name | Dorzolamide |
| Brands | 1 brand available |
| Active Ingredient | Dorzolamide hydrochloride |
| Drug Class | elevated intraocular pressure |
| Manufacturer | Merck & Co. |
| Dosage Forms | Ophthalmic solution, 2% |
| Medical Code | S01EC03 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Countries | 7 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations8 Validated Nodes